Food & Function · 2019 · 49 citations · 42 references
MedicineNutritional SciencesPlant SciencesBone MetabolismMineral MetabolismPlant PhysiologyBone Density RegulationBone EndocrinologyBone HealthBone Metabolism DisordersMetabolic Bone DiseaseOsteoporosisAnthocyanin ChemistryBone Mineral DensityBone Mineral Density DeclineEndocrine Metabolic Bone DiseaseEndocrine-related Metabolic DisordersMicrostructural Bone HistologyNutritional Effects On BoneOsteoporosis Endocrinology
) were administered by oral gavage to diabetic rats for 8 weeks. The blood glucose, BMD, bone histomorphometry parameters, serum bone turnover biomarkers, bone marrow adipocyte numbers, as well as osteoprotegerin (OPG), runt-related transcription factor 2 (RUNX 2), and receptor activator of nuclear factor-κ B ligand (RANKL) protein expression in bone and serum were detected. The results indicated that AEBR dose-dependently decreased the blood glucose, increased the BMD, and decreased the serum bone turnover markers. The bone microstructure and osteoclast numbers in bone tissues returned to normal in the high AEBR dosage group; at the same time, the AEBR dose-dependently suppressed bone marrow adipogenesis. The RUNX 2 as well as the OPG/RANKL ratio in diabetic rats' bone tissues increased significantly in the AEBR treatment group. Our results indicate that AEBR administration can ameliorate bone loss caused by diabetes; this is mainly attributed to its inhibition of bone turnover, suppression of bone marrow adipogenesis, and up-regulation of RUNX 2 and the OPG/RANKL expression ratio.
42